Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug GMP Report > Sunrise Pharmaceutical Warned After Using Excess API Amount

Drug GMP Report

February 2010

Sunrise Pharmaceutical Warned After Using Excess API Amount

Sunrise Pharmaceutical received a warning letter after manufacturing some of its products with excess active pharmaceutical ingredient (API) without justification in its batch records.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
RSS
Free Trial
Archives
Sample PDF

Related Articles

Report Pokes Holes in FDA Celexa Dose Warning Report Pokes Holes In FDA Celexa Dose Warning Report Pokes Holes in FDA Celexa Dosing Warning FDA Issues Safety Alerts on Botox, Hospira and Potiga

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.